Seattle Genetics Inc /wa (SGEN): Clay B Siegall , President and CEO of Seattle Genetics Inc /wa sold 800 shares on Apr 25, 2016. The Insider selling transaction was reported by the company on Apr 26, 2016 to the Securities and Exchange Commission. The shares were sold at $40.00 per share for a total value of $32,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 7, 2016, Clay B Siegall (President and CEO) sold 7,618 shares at $36.12 per share price.On Feb 17, 2016, John A Orwin (director) purchased 2,000 shares at $28.33 per share price.Also, On Dec 16, 2015, Vaughn B Himes (EVP, Proc Svcs & Tech Ops) sold 40,500 shares at $39.94 per share price.On Nov 13, 2015, Darren S Cline (SVP, Commercial) sold 5,769 shares at $45.68 per share price.
Seattle Genetics: On Friday, Apr 22, 2016 heightened volatility was witnessed in Seattle Genetics which led to swings in the share price. The shares opened for trading at $39.23 and hit $39.74 on the upside , eventually ending the session at $39.48, with a gain of 0.38% or 0.15 points. The heightened volatility saw the trading volume jump to 4,95,927 shares. The 52-week high of the share price is $52.3299 and the company has a market cap of $5,525 M . The 52-week low of the share price is at $26.02.
Company has been under the radar of several Street Analysts.Seattle Genetics is Initiated by Sun Trust Rbsn Humphrey to Neutral and the brokerage firm has set the Price Target at $34. The Rating was issued on Mar 3, 2016.Seattle Genetics is Upgraded by Cantor Fitzgerald to Buy. Earlier the firm had a rating of Hold on the company shares. The Rating was issued on Feb 10, 2016.Seattle Genetics is Reiterated by Piper Jaffray to Neutral while Lowering the Price Target of the company shares to $ 33 from a previous price target of $44 . The Rating was issued on Feb 10, 2016.Seattle Genetics is Reiterated by Barclays to Overweight while Lowering the Price Target of the company shares to $ 50 from a previous price target of $51 . The Rating was issued on Feb 10, 2016.Seattle Genetics is Initiated by Barclays to Overweight and the brokerage firm has set the Price Target at $51. The Rating was issued on Feb 4, 2016.
Seattle Genetics Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company’s marketed product ADCETRIS or brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent monomethyl auristatin E (MMAE) utilizing its technology. In addition to ADCETRIS the Company’s pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A SGN-CD19A SGN-LIV1A SGN-CD70A ASG-22ME and ASG-15ME and SEA-CD40 which is based on its sugar-engineered antibody (SEA) technology. In addition it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics’ sugar-engineered antibody (SEA) technology.